TrialBritish journal of cancer2022

Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.

William Jacot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.